Sorry - There were no pages found that contain that search phrase.
 |
 |
 |
 |
|
 |
Showing Treatment 1 to 25 of 42 Next 25 |
 |
Location |
 |
Last Updated |
 |
 |
 |
Details |
 |
Phase II Trial of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas
|
 |
Bethesda, MD USA |
 |
04/22/2009 |
 |
 |
 |
 |
 |
Details |
 |
A Phase I/II Trial of ZD6474 for Patients With Recurrent High-Grade and Progressive Low-Grade Gliomas
|
 |
Bethesda, MD USA |
 |
04/22/2009 |
 |
 |
 |
Details |
 |
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
|
 |
Bethesda, MD USA |
 |
04/22/2009 |
 |
 |
 |
 |
 |
Details |
 |
A Phase II Study of Pegylated Interferon Alfa-2b (PEG-INTRON) in Children With Diffuse Pontine Gliomas
|
 |
Bethesda, MD USA |
 |
04/22/2009 |
 |
 |
 |
Details |
 |
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab, Leucovorin Rescue and Highly Active Antiretroviral Therapy
|
 |
Bethesda, MD USA |
 |
04/22/2009 |
 |
 |
 |
 |
 |
Details |
 |
Multiple Ascending Dose (MAD) Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Pediatric Patients With Advanced Solid Tumors.
|
 |
Bethesda, MD USA |
 |
04/22/2009 |
 |
 |
 |
Details |
 |
A Phase I Trial and Pharmacokinetic Study of Trabectedin (Yondelis®, ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors
|
 |
Bethesda, MD USA |
 |
04/22/2009 |
 |
 |
 |
 |
 |
Details |
 |
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
 |
Baltimore, MD USA |
 |
04/21/2009 |
 |
 |
 |
Details |
 |
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
 |
Bethesda, MD USA |
 |
04/21/2009 |
 |
 |
 |
 |
 |
Details |
 |
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
 |
Bethesda, MD USA |
 |
04/21/2009 |
 |
 |
 |
Details |
 |
A Phase II Trial of Enzastaurin in Combination With Bevacizumab in Adults With Recurrent Malignant Gliomas
|
 |
Bethesda, MD USA |
 |
04/21/2009 |
 |
 |
 |
 |
 |
Details |
 |
A Phase II Trial of Bevacizumab (avastin) and Irinotecan (CPT-11) for Patients With Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment With Bevacizumab Alone: A Companion Trial to NCI Study 06-C-0064 (Bevacizumab Alone for Recurrent Gliomas)
|
 |
Bethesda, MD USA |
 |
04/21/2009 |
 |
 |
 |
Details |
 |
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas
|
 |
Bethesda, MD USA |
 |
04/21/2009 |
 |
 |
 |
 |
 |
Details |
 |
Phase II Trial of Bevacizumab (Avastin)for Patients With Recurrent High-Grade Glioma |
 |
Bethesda, MD USA |
 |
04/21/2009 |
 |
 |
 |
Details |
 |
An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma |
 |
Bethesda, MD USA |
 |
04/15/2009 |
 |
 |
 |
 |
 |
Details |
 |
Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) |
 |
Baltimore, MD USA |
 |
01/31/2009 |
 |
 |
 |
Details |
 |
Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
|
 |
Bethesda, MD USA |
 |
11/08/2008 |
 |
 |
 |
 |
 |
Details |
 |
Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma |
 |
Annapolis, MD USA |
 |
04/11/2008 |
 |
 |
 |
Details |
 |
A Pharmacokinetic and Pharmacogenomic Study of Patients With High-Grade Gliomas Receiving Daily Radiation Therapy and Temozolomide |
 |
Baltimore, MD USA |
 |
08/31/2007 |
 |
 |
 |
 |
 |
Details |
 |
Determination of the In-Tumor-Concentration of Imatinib Mesylate (Gleevec) in Malignant Glioma After Oral Administration |
 |
Baltimore, MD USA |
 |
08/20/2007 |
 |
 |
 |
Details |
 |
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel® in Subjects With Recurrent Glioma |
 |
Baltimore, MD USA |
 |
08/18/2007 |
 |
 |
 |
 |
 |
Details |
 |
Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma |
 |
Baltimore, MD USA |
 |
05/01/2007 |
 |
 |
 |
Details |
 |
Cilengitide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
 |
Baltimore, MD USA |
 |
05/01/2007 |
 |
 |
 |
 |
 |
Details |
 |
Talampanel, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
 |
Baltimore, MD USA |
 |
04/29/2007 |
 |
 |
 |
Details |
 |
Phase II Pilot Study of Adjuvant Radiotherapy and Temozolomide Followed By Temozolomide and Lomustine in Pediatric Patients With Newly Diagnosed High-Grade Gliomas |
 |
Baltimore, MD USA |
 |
04/29/2007 |
 |
 |
 |
 |
 |